bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures 1 through 8 from Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression
Authors: Lenhart Ryan , Kirov Stefan , Desilva Heshani , Cao Jian , Lei Ming , Johnston Kathy , Peterson Russell , Schweizer Liang , Purandare Ashok , Ross-Macdonald Petra , Fairchild Craig , Wong Tai , Wee Susan
Published: April 2023

Figure S1. Potency of I-BET762 in inhibition of proliferation of lung tumor cell lines. Lineage of lung cell lines is as indicated. Figure S2. Dose response curves of JQ1 in cell proliferation assays. Shown are examples of lung tumor cell lines with different sensitivity to JQ1. Figure S3. Induction of apoptosis in four SCLC cell lines was monitored by caspase 3 and 7 cleavage after 72 h treatment with JQ1. Data shown are fold changes over DMSO control. Figure S4. Probe sets induced by JQ1 in SCLC cell lines. Shown are microarray data for three probe sets that were induced by JQ1. Figure S5. Examples of probe sets that show dose-dependent changes, but were expressed only at background levels (RNF183) in all four cell lines, or were expressed at low levels in the sensitive cell lines (NR0B2). Figure S6. Dose response in expression of the three ASCL1 probe sets upon JQ1 treatment. Figure S7. (A) Enrichment of BRD4 binding at the ASCL1 gene enhancer compared to a gene desert on the same chromosome. Primers specific for ASCL1 enhancer or a gene desert on chromosome 12 were used to detect BRD4 binding. (B) JQ1 has no effect on non-specific binding of BRD4 to a gene desert in SCLC cell lines. Figure S8. (A) ASCL1 mRNA in SCLC and non-small-cell lung neuroendocrine (UMC-11 and NCI-H1155) cell lines. JQ1 sensitivity cut-off is arbitrarily defined as an IC50 of 0.5 µM. (B) ASCL1 protein abundance in SCLC cell lines that are sensitive or resistant to JQ1. (C) UMC-11 cells were treated with JQ1 for 24h and ASCL1 protein was analyzed by western blotting.
Supplementary Figure Legend from Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression
Authors: Lenhart Ryan , Kirov Stefan , Desilva Heshani , Cao Jian , Lei Ming , Johnston Kathy , Peterson Russell , Schweizer Liang , Purandare Ashok , Ross-Macdonald Petra , Fairchild Craig , Wong Tai , Wee Susan
Published: April 2023

Legend for Supplementary Tables 1 and 2 and Supplementary Figures 1 through 8
Table S1 from Effective Inhibition of Bone Morphogenetic Protein Function by Highly Specific Llama-Derived Antibodies
Authors: Calpe Silvia , Wagner Koen , El Khattabi Mohamed , Rutten Lucy , Zimberlin Cheryl , Dolk Edward , Verrips C. Theo , Medema Jan Paul , Spits Hergen , Krishnadath Kausilia K.
Published: April 2023

Summary of epitope binning experiments of the VHHs and controls
Supplemental Figure 2 from MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
Authors: Xiao Yu , Nimmer Paul , Sheppard George S. , Bruncko Milan , Hessler Paul , Lu Xin , Roberts-Rapp Lisa , Pappano William N. , Elmore Steven W. , Souers Andrew J. , Leverson Joel D. , Phillips Darren C.
Published: April 2023

Supplemental Figure 2: The susceptibility of breast cancer cell lines to MCL-1 siRNA according to genotype and expression of BCL-2 family members.
Supplemental Figure 1 from MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
Authors: Xiao Yu , Nimmer Paul , Sheppard George S. , Bruncko Milan , Hessler Paul , Lu Xin , Roberts-Rapp Lisa , Pappano William N. , Elmore Steven W. , Souers Andrew J. , Leverson Joel D. , Phillips Darren C.
Published: April 2023

Supplemental Figure 1: Validation of MCL-1 siRNA.
Figure S5 from Effective Inhibition of Bone Morphogenetic Protein Function by Highly Specific Llama-Derived Antibodies
Authors: Calpe Silvia , Wagner Koen , El Khattabi Mohamed , Rutten Lucy , Zimberlin Cheryl , Dolk Edward , Verrips C. Theo , Medema Jan Paul , Spits Hergen , Krishnadath Kausilia K.
Published: April 2023

Epitope mapping using BMP heterodimers (BMP4/7, BMP2/6 and BMP2/7).
List of Supplementary Figure Legends from MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
Authors: Xiao Yu , Nimmer Paul , Sheppard George S. , Bruncko Milan , Hessler Paul , Lu Xin , Roberts-Rapp Lisa , Pappano William N. , Elmore Steven W. , Souers Andrew J. , Leverson Joel D. , Phillips Darren C.
Published: April 2023

List of Supplementary Figure Legends. Figure legend information.
Figure S4 from Effective Inhibition of Bone Morphogenetic Protein Function by Highly Specific Llama-Derived Antibodies
Authors: Calpe Silvia , Wagner Koen , El Khattabi Mohamed , Rutten Lucy , Zimberlin Cheryl , Dolk Edward , Verrips C. Theo , Medema Jan Paul , Spits Hergen , Krishnadath Kausilia K.
Published: April 2023

Space-filled view of binding of BMP2 and BMPR1 and BMPR2. Sequence comparison of the different BMPs.
Supplementary Figure Legend from Berberine Induces Senescence of Human Glioblastoma Cells by Downregulating the EGFR–MEK–ERK Signaling Pathway
Authors: Liu Qiao , Xu Xiuhua , Zhao Minnan , Wei Zhao , Li Xi , Zhang Xiyu , Liu Zhaojian , Gong Yaoqin , Shao Changshun
Published: April 2023

Legend to supplementary figures
Figure S2 from Effective Inhibition of Bone Morphogenetic Protein Function by Highly Specific Llama-Derived Antibodies
Authors: Calpe Silvia , Wagner Koen , El Khattabi Mohamed , Rutten Lucy , Zimberlin Cheryl , Dolk Edward , Verrips C. Theo , Medema Jan Paul , Spits Hergen , Krishnadath Kausilia K.
Published: April 2023

Specificity of VHHs to BMP2, BMP4, BMP5 , BMP6 and BMP7 at higher concentrations.
Figure S1 from Effective Inhibition of Bone Morphogenetic Protein Function by Highly Specific Llama-Derived Antibodies
Authors: Calpe Silvia , Wagner Koen , El Khattabi Mohamed , Rutten Lucy , Zimberlin Cheryl , Dolk Edward , Verrips C. Theo , Medema Jan Paul , Spits Hergen , Krishnadath Kausilia K.
Published: April 2023

Comparison of pSMAD1/5/8 inhibition by western blot between monoheads and biheads at different concentrations.
Figure S2 from Berberine Induces Senescence of Human Glioblastoma Cells by Downregulating the EGFR–MEK–ERK Signaling Pathway
Authors: Liu Qiao , Xu Xiuhua , Zhao Minnan , Wei Zhao , Li Xi , Zhang Xiyu , Liu Zhaojian , Gong Yaoqin , Shao Changshun
Published: April 2023

Figure S2. Downregulation of EGFR by berberine is not caused by reduced transcription
Supplementary Table 1 and Supplementary Figure 1 from Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors
Authors: Feneyrolles Clémence , Spenlinhauer Aurélia , Guiet Léa , Fauvel Bénédicte , Daydé-Cazals Bénédicte , Warnault Pierre , Chevé Gwénaël , Yasri Aziz
Published: April 2023

Supplementary data gathers supplementary table 1 and supplementary figure 1. Supplementary table 1: inhibition profile relationship for Axl related to sequence identity. Supplementary figure 1: structure of the described Axl's inhibitors
Supplementary Figure Legends from Small Molecule Inhibitor YM155-Mediated Activation of Death Receptor 5 Is Crucial for Chemotherapy-Induced Apoptosis in Pancreatic Carcinoma
Authors: Zhao Xiangxuan , Puszyk William M. , Lu Zaiming , Ostrov David A. , George Thomas J. , Robertson Keith D. , Liu Chen
Published: April 2023

Supplementary Figure legends for figures S1 and S2. Figure S1 Legend provides experimental information for the effect of YM155 on Panc-1 cells. Figure S2 Legend provides experimental information for the effect of YM155 on PC-3 cells.
Supplementary Figure S7 from A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages
Authors: Hayashi Noriyuki , Kataoka Hiromi , Yano Shigenobu , Tanaka Mamoru , Moriwaki Kazuhiro , Akashi Haruo , Suzuki Shugo , Mori Yoshinori , Kubota Eiji , Tanida Satoshi , Takahashi Satoru , Joh Takashi
Published: April 2023

Excess mannose reduced binding of M-chlorin to the macrophages and tumor cells in a dose-dependent manner.
Supplementary Table 1-5 from HMDB and 5-AzadC Combination Reverses Tumor Suppressor CCAAT/Enhancer-Binding Protein Delta to Strengthen the Death of Liver Cancer Cells
Authors: Li Chien-Feng , Tsai Hsin-Hwa , Ko Chiung-Yuan , Pan Yen-Chun , Yen Chia-Jui , Lai Hong-Yue , Yuh Chiou-Hwa , Wu Wan-Chen , Wang Ju-Ming
Published: April 2023

Supplementary Table 1. Expression of CEBPD and its correlation with clinicopathological parameters. Supplementary Table 2. Univariate log rank analysis for prognostic factors in 90 patients with follow-up. Supplementary Table 3. Multivariate survival analyses for prognostic factors in 90 patients with follow-up. Supplementary Table 4: List of primer sequences Supplementary Table 5: List of antibodies for Western blot
Supplementary Figure S6 from A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages
Authors: Hayashi Noriyuki , Kataoka Hiromi , Yano Shigenobu , Tanaka Mamoru , Moriwaki Kazuhiro , Akashi Haruo , Suzuki Shugo , Mori Yoshinori , Kubota Eiji , Tanida Satoshi , Takahashi Satoru , Joh Takashi
Published: April 2023

M-chlorin tended to accumulate with CD206 expressing TAMs.
Supplementary Method from HMDB and 5-AzadC Combination Reverses Tumor Suppressor CCAAT/Enhancer-Binding Protein Delta to Strengthen the Death of Liver Cancer Cells
Authors: Li Chien-Feng , Tsai Hsin-Hwa , Ko Chiung-Yuan , Pan Yen-Chun , Yen Chia-Jui , Lai Hong-Yue , Yuh Chiou-Hwa , Wu Wan-Chen , Wang Ju-Ming
Published: April 2023

Supplementary Methods
Supplementary Figure legends from HMDB and 5-AzadC Combination Reverses Tumor Suppressor CCAAT/Enhancer-Binding Protein Delta to Strengthen the Death of Liver Cancer Cells
Authors: Li Chien-Feng , Tsai Hsin-Hwa , Ko Chiung-Yuan , Pan Yen-Chun , Yen Chia-Jui , Lai Hong-Yue , Yuh Chiou-Hwa , Wu Wan-Chen , Wang Ju-Ming
Published: April 2023

Supplementary Figure legends
Supplementary Figure S4 from A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages
Authors: Hayashi Noriyuki , Kataoka Hiromi , Yano Shigenobu , Tanaka Mamoru , Moriwaki Kazuhiro , Akashi Haruo , Suzuki Shugo , Mori Yoshinori , Kubota Eiji , Tanida Satoshi , Takahashi Satoru , Joh Takashi
Published: April 2023

Western blotting of nuclear protein showed that PDT with M-chlorin increased nuclear translocation of Nrf2 gradually from 0.5 h onward after therapy.
Supplementary Figure S2 from A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages
Authors: Hayashi Noriyuki , Kataoka Hiromi , Yano Shigenobu , Tanaka Mamoru , Moriwaki Kazuhiro , Akashi Haruo , Suzuki Shugo , Mori Yoshinori , Kubota Eiji , Tanida Satoshi , Takahashi Satoru , Joh Takashi
Published: April 2023

Subcellular localization of G-chlorin.
Supplementary Figure S1 from A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages
Authors: Hayashi Noriyuki , Kataoka Hiromi , Yano Shigenobu , Tanaka Mamoru , Moriwaki Kazuhiro , Akashi Haruo , Suzuki Shugo , Mori Yoshinori , Kubota Eiji , Tanida Satoshi , Takahashi Satoru , Joh Takashi
Published: April 2023

Cell survival curves following photodynamic therapy.
Supplementary Figures S1-S4 and Supplementary Methods from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
Authors: Pereira Daniel S. , Guevara Claudia I. , Jin Liqing , Mbong Nathan , Verlinsky Alla , Hsu Ssucheng J. , Aviña Hector , Karki Sher , Abad Joseph D. , Yang Peng , Moon Sung-Ju , Malik Faisal , Choi Michael Y. , An Zili , Morrison Kendall , Challita-Eid Pia M. , Doñate Fernando , Joseph Ingrid B.J. , Kipps Thomas J. , Dick John E. , Stover David R.
Published: April 2023

Figure S1: AGS67E Binds To B-Cells With High Affinity and Induces Cytotoxicity. Figure S2: AGS67E and AGS67C Internalize Into B Cell Lymphma Cells. Figure S3: AGS67E But Not AGS67C Exhibits Anti-Tumor Activity In MOLM-13 Xenografts. Figure S4: AGS67C IgG1 But Not IgG2 Induces ADCC Activity.
Supplementary Figure Legends from A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages
Authors: Hayashi Noriyuki , Kataoka Hiromi , Yano Shigenobu , Tanaka Mamoru , Moriwaki Kazuhiro , Akashi Haruo , Suzuki Shugo , Mori Yoshinori , Kubota Eiji , Tanida Satoshi , Takahashi Satoru , Joh Takashi
Published: April 2023

Supplementary Figure Legends of Fig. S1 to Fig. S7.
Supplementary Information from Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody
Authors: Zhang Zheng , Zhang Yang , Sun Qian , Feng Fei , Huhe Muren , Mi Li , Chen Zhinan
Published: April 2023

Supplementary Information. including Materials and methods
Supplementary Tables 1 through 6 from Elevated LIM Kinase 1 in Nonmetastatic Prostate Cancer Reflects Its Role in Facilitating Androgen Receptor Nuclear Translocation
Authors: Mardilovich Katerina , Gabrielsen Mads , McGarry Lynn , Orange Clare , Patel Rachana , Shanks Emma , Edwards Joanne , Olson Michael F.
Published: April 2023

Supplemental Table S1. Demographic, clinicopathological and outcome data. Supplemental Table S2. LIMK1 association with prostate cancer patient survival. Supplemental Table S3. LIMK2 association with prostate cancer patient survival. Supplemental Table S4. Nuclear phosphorylated Cofilin association with prostate cancer patient survival. Supplemental Table S5. Cytoplasmic phosphorylated Cofilin association with prostate cancer patient survival. Supplemental Table S6. Associations between immunohistochemistry scores and clinicopathological parameters.
Supplementary Figure S2 from Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody
Authors: Zhang Zheng , Zhang Yang , Sun Qian , Feng Fei , Huhe Muren , Mi Li , Chen Zhinan
Published: April 2023

Supplementary Figure S2. Metuzumab has potent ADCC activity with murine PBMCs and macrophages/monocytes. The ability of Metuzumab mediated in vitro ADCC by human PBMCs (hPBMCs), murine PMBCs (mPBMCs), murine NK cells, or murine macrophages/monocytes were measured using LDH release assay. A549 and NCI-H520 cells were used as target cells in a 30:1 effector/target ratio (5:1 when NK cells or macrophages/monocytes were used as effectors). The results are shown as the mean values {plus minus} S.D. and are representative of 6 independent experiments.
Supplementary Figure S1 from Elevated LIM Kinase 1 in Nonmetastatic Prostate Cancer Reflects Its Role in Facilitating Androgen Receptor Nuclear Translocation
Authors: Mardilovich Katerina , Gabrielsen Mads , McGarry Lynn , Orange Clare , Patel Rachana , Shanks Emma , Edwards Joanne , Olson Michael F.
Published: April 2023

Supplementary Figure S1: Antibody validation data, disease free progression data, and LIMK1, LIMK2 and metalloproteinase protein expression data.
Supplementary Table S7 from Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Authors: Gridling Manuela , Ficarro Scott B. , Breitwieser Florian P. , Song Lanxi , Parapatics Katja , Colinge Jacques , Haura Eric B. , Marto Jarrod A. , Superti-Furga Giulio , Bennett Keiryn L. , Rix Uwe
Published: April 2023

Table S7. Mass spectrometry data of phosphoproteomics experiments with eluates from c-dasatinib and c-sunitinib affinity chromatography eluates across all samples from primary NSCLC tissues, cell lines and cell line-derived mouse xenografts.
Supplementary Table S1 and Fig S1 and S2 from Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Authors: Kwon Yeon-Jin , Petrie Kevin , Leibovitch Boris A. , Zeng Lei , Mezei Mihaly , Howell Louise , Gil Veronica , Christova Rossitza , Bansal Nidhi , Yang Shuai , Sharma Rajal , Ariztia Edgardo V. , Frankum Jessica , Brough Rachel , Sbirkov Yordan , Ashworth Alan , Lord Christopher J. , Zelent Arthur , Farias Eduardo , Zhou Ming-Ming , Waxman Samuel
Published: April 2023

Supplementary Table S1 and Fig S1 and S2. Supplementary Table 1: qPCR primers used in this study; Supplementary Figure S1: Structures of compounds screened in Figure 1A and 1B; Supplementary Figure S2: Proximity ligation assay (PLA) analyzing SIN3A-MAD interactions
Supplementary Table S5 from Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Authors: Gridling Manuela , Ficarro Scott B. , Breitwieser Florian P. , Song Lanxi , Parapatics Katja , Colinge Jacques , Haura Eric B. , Marto Jarrod A. , Superti-Furga Giulio , Bennett Keiryn L. , Rix Uwe
Published: April 2023

Table S5. Mass spectrometry data of chemical proteomics experiments with c-dasatinib and c-sunitinib in mouse xenograft samples of H23 and H292 cell lines.
Data Supplement from Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)
Authors: Huck Jessica J. , Zhang Mengkun , Mettetal Jerome , Chakravarty Arijit , Venkatakrishnan Karthik , Zhou Xiaofei , Kleinfield Rob , Hyer Marc L. , Kannan Karuppiah , Shinde Vaishali , Dorner Andy , Manfredi Mark G. , Shyu Wen Chyi , Ecsedy Jeffrey A.
Published: April 2023

Supplementary Figure 1. Sample simulated time-course of paclitaxel and MLN8237 PK after and the pharmacokinetic parameters used for MLN8237 and paclitaxel required to generate the exposure - efficacy model. Supplementary Figure 2. Predicted versus observed % TGI resulting from the best fit of the dose response surface to the xenograft tumor growth data. Supplementary Figure 3. Cleaved caspase 3 staining of tumor xenografts following single agent or combination treatment with MLN8237 and docetaxel in the PHTX-14B and MDA-MB-231 xenografts. Supplementary Figure 4. MLN8237 administered on an intermittent 3 days on / 4 days off schedule combined with paclitaxel results in additive antitumor activity in the MDA-MB-231 model. Supplementary Figure 5. MLN8237 and paclitaxel exposures are similar when dosed alone or in combination.
Supplementary Table S4 from Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Authors: Gridling Manuela , Ficarro Scott B. , Breitwieser Florian P. , Song Lanxi , Parapatics Katja , Colinge Jacques , Haura Eric B. , Marto Jarrod A. , Superti-Furga Giulio , Bennett Keiryn L. , Rix Uwe
Published: April 2023

Table S4. Comparison of dasatinib and sunitinib targets between NSCLC, leukemia and melanoma cell lines.
Supplementary Table S3 from Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Authors: Gridling Manuela , Ficarro Scott B. , Breitwieser Florian P. , Song Lanxi , Parapatics Katja , Colinge Jacques , Haura Eric B. , Marto Jarrod A. , Superti-Furga Giulio , Bennett Keiryn L. , Rix Uwe
Published: April 2023

Table S3. Mass spectrometry data of chemical proteomics experiments with c-dasatinib and c-sunitinib in H23 and H292 cell line samples.
Data Supplement from Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)
Authors: Huck Jessica J. , Zhang Mengkun , Mettetal Jerome , Chakravarty Arijit , Venkatakrishnan Karthik , Zhou Xiaofei , Kleinfield Rob , Hyer Marc L. , Kannan Karuppiah , Shinde Vaishali , Dorner Andy , Manfredi Mark G. , Shyu Wen Chyi , Ecsedy Jeffrey A.
Published: April 2023

Supplementary Figure Legends describing Supplementary Figures 1-5.
Supplementary Figure 5 from SRT1720 Induces Lysosomal-Dependent Cell Death of Breast Cancer Cells
Authors: Lahusen Tyler J. , Deng Chu-Xia
Published: April 2023

Supplementary Figure 5. Cell viability of WT and ATF3-/- MEFs treated with SRT1720
Supplementary Table S1 from Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Authors: Gridling Manuela , Ficarro Scott B. , Breitwieser Florian P. , Song Lanxi , Parapatics Katja , Colinge Jacques , Haura Eric B. , Marto Jarrod A. , Superti-Furga Giulio , Bennett Keiryn L. , Rix Uwe
Published: April 2023

Table S1. Mutational status of all specimens regarding KRAS and EGFR.
Supplementary Figure 4 from SRT1720 Induces Lysosomal-Dependent Cell Death of Breast Cancer Cells
Authors: Lahusen Tyler J. , Deng Chu-Xia
Published: April 2023

Supplementary Figure 4. Cell viability of Hs578T breast cancer cells treated with SRT1720 and the lysosomal inhibitor, ammonium chloride
Supplementary Legends from Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Authors: Gridling Manuela , Ficarro Scott B. , Breitwieser Florian P. , Song Lanxi , Parapatics Katja , Colinge Jacques , Haura Eric B. , Marto Jarrod A. , Superti-Furga Giulio , Bennett Keiryn L. , Rix Uwe
Published: April 2023

Legends for Supplementary Figures and Tables
Supplementary Figure S2 from Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Authors: Gridling Manuela , Ficarro Scott B. , Breitwieser Florian P. , Song Lanxi , Parapatics Katja , Colinge Jacques , Haura Eric B. , Marto Jarrod A. , Superti-Furga Giulio , Bennett Keiryn L. , Rix Uwe
Published: April 2023

Figure S2. Global tissue expression profiles of selected kinases.
Supplementary Figure 2 from SRT1720 Induces Lysosomal-Dependent Cell Death of Breast Cancer Cells
Authors: Lahusen Tyler J. , Deng Chu-Xia
Published: April 2023

Supplementary Figure 2. Control and SIRT1 knockdown MDA-MB-231 cells treated with a dose range of resveratrol for 24 hours
Supplementary Figure 1 from SRT1720 Induces Lysosomal-Dependent Cell Death of Breast Cancer Cells
Authors: Lahusen Tyler J. , Deng Chu-Xia
Published: April 2023

Supplementary Figure 1. Cell density affects the sensitivity of MDA-MB-231 cells to SRT1720 treatment
Supplementary Tables S1-S2 from Rho Guanine Nucleotide Exchange Factor 5 Increases Lung Cancer Cell Tumorigenesis via MMP-2 and Cyclin D1 Upregulation
Authors: He Ping , Wu Wei , Yang Kang , Tan Deli , Tang Meng , Liu Hongxiang , Wu Tao , Zhang Shixin , Wang Haidong
Published: April 2023

Supplementary Tables S1-S2. Table S1. Baseline characteristics of the lung adenocarcinoma patients Table S2. Incidence of lung metastasis in nude mice subcutaneously injected ARHGEF5 knock-down (RNAi) or control (Par) A549 or H1650 cells.
Supplementary Figure legend from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
Authors: Adelaiye Remi , Ciamporcero Eric , Miles Kiersten Marie , Sotomayor Paula , Bard Jonathan , Tsompana Maria , Conroy Dylan , Shen Li , Ramakrishnan Swathi , Ku Sheng-Yu , Orillion Ashley , Prey Joshua , Fetterly Gerald , Buck Michael , Chintala Sreenivasulu , Bjarnason Georg A. , Pili Roberto
Published: April 2023

Supplementary Figure legend
Supplementary Fig. 6 from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
Authors: Adelaiye Remi , Ciamporcero Eric , Miles Kiersten Marie , Sotomayor Paula , Bard Jonathan , Tsompana Maria , Conroy Dylan , Shen Li , Ramakrishnan Swathi , Ku Sheng-Yu , Orillion Ashley , Prey Joshua , Fetterly Gerald , Buck Michael , Chintala Sreenivasulu , Bjarnason Georg A. , Pili Roberto
Published: April 2023

Supplementary Fig. 6. Histone marks expression in sunitinib resistant RP-R-01 tumors
Supplementary Table 2 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
Authors: Scales Suzie J. , Gupta Nidhi , Pacheco Glenn , Firestein Ron , French Dorothy M. , Koeppen Hartmut , Rangell Linda , Barry-Hamilton Vivian , Luis Elizabeth , Chuh Josefa , Zhang Yin , Ingle Gladys S. , Fourie-O'Donohue Aimee , Kozak Katherine R. , Ross Sarajane , Dennis Mark S. , Spencer Susan D.
Published: April 2023

Supplementary Table 2: Details of in vivo efficacy studies (# cells implanted; mouse strain, age and weight; tumor randomization volumes and IHC scores; % tumor growth inhibition and time to doubling versus vehicle).
Supplementary Fig. 5 from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
Authors: Adelaiye Remi , Ciamporcero Eric , Miles Kiersten Marie , Sotomayor Paula , Bard Jonathan , Tsompana Maria , Conroy Dylan , Shen Li , Ramakrishnan Swathi , Ku Sheng-Yu , Orillion Ashley , Prey Joshua , Fetterly Gerald , Buck Michael , Chintala Sreenivasulu , Bjarnason Georg A. , Pili Roberto
Published: April 2023

Supplementary Fig. 5. Histone marks expression associated with resistance to sunitinib
Supplementary Fig. 2 from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
Authors: Adelaiye Remi , Ciamporcero Eric , Miles Kiersten Marie , Sotomayor Paula , Bard Jonathan , Tsompana Maria , Conroy Dylan , Shen Li , Ramakrishnan Swathi , Ku Sheng-Yu , Orillion Ashley , Prey Joshua , Fetterly Gerald , Buck Michael , Chintala Sreenivasulu , Bjarnason Georg A. , Pili Roberto
Published: April 2023

Supplementary Fig. 2. Tumor growth of RP-R-01 ccRCC xenograft treated with sunitinib and associated changes in EZH2, H3K27me3 and E-cadherin expression.
Supplementary Materials and Methods and Supplementary Figure Legends from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
Authors: Scales Suzie J. , Gupta Nidhi , Pacheco Glenn , Firestein Ron , French Dorothy M. , Koeppen Hartmut , Rangell Linda , Barry-Hamilton Vivian , Luis Elizabeth , Chuh Josefa , Zhang Yin , Ingle Gladys S. , Fourie-O'Donohue Aimee , Kozak Katherine R. , Ross Sarajane , Dennis Mark S. , Spencer Susan D.
Published: April 2023

Supplemental ancillary methods (ELISA, surface plasmon resonance and humanization) and 4 supplemental figure legends.
Supplementary Figure 4 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
Authors: Scales Suzie J. , Gupta Nidhi , Pacheco Glenn , Firestein Ron , French Dorothy M. , Koeppen Hartmut , Rangell Linda , Barry-Hamilton Vivian , Luis Elizabeth , Chuh Josefa , Zhang Yin , Ingle Gladys S. , Fourie-O'Donohue Aimee , Kozak Katherine R. , Ross Sarajane , Dennis Mark S. , Spencer Susan D.
Published: April 2023

Supplementary Figure 4: Western blots of cell lines and xenografts used in Figure 5.
Supplementary Figure 6 from Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer
Authors: Molloy Mary Ellen , White Bethany E. Perez , Gherezghiher Teshome , Michalsen Bradley T. , Xiong Rui , Patel Hitisha , Zhao Huiping , Maximov Philipp Y. , Jordan V. Craig , Thatcher Gregory R.J. , Tonetti Debra A.
Published: April 2023

Supplementary Figure 6: Plasma concentration-time profile of BTC following the administration of a single oral dose of 10 mg/Kg BTC to mice. Each data point represents the mean value {plus minus} SD (n = 3).
Supplementary Figure 5 from Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer
Authors: Molloy Mary Ellen , White Bethany E. Perez , Gherezghiher Teshome , Michalsen Bradley T. , Xiong Rui , Patel Hitisha , Zhao Huiping , Maximov Philipp Y. , Jordan V. Craig , Thatcher Gregory R.J. , Tonetti Debra A.
Published: April 2023

Supplementary Figure 5: (A) Total ion chromatogram; (B) BTC (25 ng/mL) in mouse plasma; and (C) IS Br-BTC (20 ng/mL).
Suuplementary Movie SM2 from Tumor-Penetrating iRGD Peptide Inhibits Metastasis
Authors: Sugahara Kazuki N. , Braun Gary B. , de Mendoza Tatiana Hurtado , Kotamraju Venkata Ramana , French Randall P. , Lowy Andrew M. , Teesalu Tambet , Ruoslahti Erkki
Published: April 2023

Suuplementary Movie SM2. Collapse of cellular protrusions upon interaction with iRGD silver nanoparticles
Supplementary Movie SM5 from Tumor-Penetrating iRGD Peptide Inhibits Metastasis
Authors: Sugahara Kazuki N. , Braun Gary B. , de Mendoza Tatiana Hurtado , Kotamraju Venkata Ramana , French Randall P. , Lowy Andrew M. , Teesalu Tambet , Ruoslahti Erkki
Published: April 2023

Supplementary Movie SM5. Tumor cell migration on plain silver nanoparticles
Supplementary Figure 3 from Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer
Authors: Molloy Mary Ellen , White Bethany E. Perez , Gherezghiher Teshome , Michalsen Bradley T. , Xiong Rui , Patel Hitisha , Zhao Huiping , Maximov Philipp Y. , Jordan V. Craig , Thatcher Gregory R.J. , Tonetti Debra A.
Published: April 2023

Supplementary Figure 3: Reagents and conditions: (a) N-Bromoacetamide, DCM, EtOH, rt; (b) BBr3, dry DCM, 0sup>; (c) Dansyl chloride, TEA, DCM, 60 sup>C.
Supplementary Movie SM3 from Tumor-Penetrating iRGD Peptide Inhibits Metastasis
Authors: Sugahara Kazuki N. , Braun Gary B. , de Mendoza Tatiana Hurtado , Kotamraju Venkata Ramana , French Randall P. , Lowy Andrew M. , Teesalu Tambet , Ruoslahti Erkki
Published: April 2023

Supplementary Movie SM3. Tumor cell repulsion from iRGD silver nanoparticles
Supplementary Movie SM1 from Tumor-Penetrating iRGD Peptide Inhibits Metastasis
Authors: Sugahara Kazuki N. , Braun Gary B. , de Mendoza Tatiana Hurtado , Kotamraju Venkata Ramana , French Randall P. , Lowy Andrew M. , Teesalu Tambet , Ruoslahti Erkki
Published: April 2023

Supplementary Movie SM1. Tumor cell migration on iRGD silver nanoparticles
Supplementary Table 4 from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
Authors: Huynh Hung , Hao Huai-Xiang , Chan Stephen L. , Chen David , Ong Richard , Soo Khee Chee , Pochanard Panisa , Yang David , Ruddy David , Liu Manway , Derti Adnan , Balak Marissa N. , Palmer Michael R. , Wang Yan , Lee Benjamin H. , Sellami Dalila , Zhu Andrew X. , Schlegel Robert , Huang Alan
Published: April 2023

Genetic characterization of 35 established HCC PTX models by targeted DNA sequencing (Excel file).
Supplementary Table S1 from Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic
Authors: Kearns Jeffrey D. , Bukhalid Raghida , Sevecka Mark , Tan Gege , Gerami-Moayed Nastaran , Werner Shannon L. , Kohli Neeraj , Burenkova Olga , Sloss Callum M. , King Anne M. , Fitzgerald Jonathan B. , Nielsen Ulrik B. , Wolf Beni B.
Published: April 2023

Supplementary Table S1. Cell lines and cell culture conditions
Supplementary Methods, Figures S1-S11, and Table Legends from Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic
Authors: Kearns Jeffrey D. , Bukhalid Raghida , Sevecka Mark , Tan Gege , Gerami-Moayed Nastaran , Werner Shannon L. , Kohli Neeraj , Burenkova Olga , Sloss Callum M. , King Anne M. , Fitzgerald Jonathan B. , Nielsen Ulrik B. , Wolf Beni B.
Published: April 2023

Supplementary Methods, Figures S1-S11, and Table Legends. Supplementary Methods: description of methods used in the Supplementary figures, expanded description of ELISA assays, and description of the computational model of multiple EGFR ligand antagonists. Supplementary Figure S1: Monoclonal EGFR antibodies poorly block signal amplification by high-affinity EGFR ligands. Supplementary Figure S2: Hierarchical clustering of EGFR ligand expression in primary colon, head and neck, and lung tumors. Supplementary Figure S3: Trends observed in EGFR ligand expression in TCGA data set are similarly apparent in primary colorectal samples analyzed by RT-qPCR. Supplementary Figure S4: Relative expression of EGFR ligands varies across cancer indications. Supplementary Figure S5: Simulated activity of a combination of two ligand antagonists versus single antagonists as a function of ligand affinity. Supplementary Figure S6: MM-151 antibodies have non-overlapping epitopes and can simultaneously engage the same EGF receptor molecule. Supplementary Figure S7: MM-151 elicits superior ligand antagonism. Supplementary Figure S8: MM-151 promotes potent down-regulation of EGFR that is dependent upon the oligoclonal combination of bivalent antibodies. Supplementary Figure S9: MM-151 promotes both antibody-dependent cell-mediated (ADCC) and complement-dependent (CDC) cytotoxicity. Supplementary Figure S10: Cell proliferation stimulated by high-affinity ligands is partially or completely resistant to cetuximab treatment but still sensitive to MM-151 treatment. Supplementary Figure S11: MM-151 overcomes signal amplification driven by high-affinity ligand. Legends for Supplementary Tables S1-S8.
Supplementary Methods and Legend from HAb18G/CD147 Promotes Radioresistance in Hepatocellular Carcinoma Cells: A Potential Role for Integrin β1 Signaling
Authors: Wu Jiao , Li Yong , Dang Ya-Zheng , Gao Hong-Xiang , Jiang Jian-Li , Chen Zhi-Nan
Published: April 2023

Supplementary Methods and Legend for Fig S1
Supplementary Figure 4 from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
Authors: Huynh Hung , Hao Huai-Xiang , Chan Stephen L. , Chen David , Ong Richard , Soo Khee Chee , Pochanard Panisa , Yang David , Ruddy David , Liu Manway , Derti Adnan , Balak Marissa N. , Palmer Michael R. , Wang Yan , Lee Benjamin H. , Sellami Dalila , Zhu Andrew X. , Schlegel Robert , Huang Alan
Published: April 2023

Race distribution of HCC patients in EVOLVE-1 trial. Percentage of Caucasian, Asian and other race in different groups of EVOLVE-1 patients (A) and TSC2 IHC H-score ranges (B).
Supplementary Figure 3 from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
Authors: Huynh Hung , Hao Huai-Xiang , Chan Stephen L. , Chen David , Ong Richard , Soo Khee Chee , Pochanard Panisa , Yang David , Ruddy David , Liu Manway , Derti Adnan , Balak Marissa N. , Palmer Michael R. , Wang Yan , Lee Benjamin H. , Sellami Dalila , Zhu Andrew X. , Schlegel Robert , Huang Alan
Published: April 2023

TSC2 immunohistochemistry assay validation and analysis of HCC xenograft and primary tumors. (A) TSC2 immunohistochemistry (IHC) assay with HCC cell lines. (B) TSC2 IHC assay with HCC xenograft tumors. (C) TSC2 expression by IHC assay in HCC xenografts and their corresponding primary tumors.
Supplementary Figure 1 from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
Authors: Huynh Hung , Hao Huai-Xiang , Chan Stephen L. , Chen David , Ong Richard , Soo Khee Chee , Pochanard Panisa , Yang David , Ruddy David , Liu Manway , Derti Adnan , Balak Marissa N. , Palmer Michael R. , Wang Yan , Lee Benjamin H. , Sellami Dalila , Zhu Andrew X. , Schlegel Robert , Huang Alan
Published: April 2023

TSC2 loss in HCC cell lines leads to mTOR activation. (A) Reverse Phase Protein Array (RPPA) analysis of nine HCC cell lines for TSC2 protein levels and phosphorylation levels of S6K1, 4E-BP1, S6 and AKT. (B) Immunoblot of TSC2 wild-type HuH-7 cells treated with inhibitors of PI3K, AKT or MEK. (C) p-S6K1(T389) immunoblot of TSC2-null HCC cell lines treated with varying concentrations of everolimus.
Supplementary Tablea 5 and 6 from miR200c Attenuates P-gp–Mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer
Authors: Sui Hua , Cai Guo-Xiang , Pan Shu-Fang , Deng Wan-Li , Wang Yu-Wei , Chen Zhe-Sheng , Cai San-Jun , Zhu Hui-Rong , Li Qi
Published: April 2023

Supplementary Tables 5 and 6: Patient information on the samples used in the main manuscript.
Supplementary Figure 2 from Context Dependence of Checkpoint Kinase 1 as a Therapeutic Target for Pancreatic Cancers Deficient in the BRCA2 Tumor Suppressor
Authors: Hattori Hiroyoshi , Skoulidis Ferdinandos , Russell Paul , Venkitaraman Ashok R.
Published: April 2023

Supplementary Figure 2 from Context Dependence of Checkpoint Kinase 1 as a Therapeutic Target for Pancreatic Cancers Deficient in the BRCA2 Tumor Suppressor
Supplementary Figure 1 from Context Dependence of Checkpoint Kinase 1 as a Therapeutic Target for Pancreatic Cancers Deficient in the BRCA2 Tumor Suppressor
Authors: Hattori Hiroyoshi , Skoulidis Ferdinandos , Russell Paul , Venkitaraman Ashok R.
Published: April 2023

Supplementary Figure 1 from Context Dependence of Checkpoint Kinase 1 as a Therapeutic Target for Pancreatic Cancers Deficient in the BRCA2 Tumor Suppressor
Supplementary materials and methods from Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC
Authors: Zhou Hong , Mohamedali Khalid A. , Gonzalez-Angulo Ana Maria , Cao Yu , Migliorini Mary , Cheung Lawrence H. , LoBello Janine , Lei Xiudong , Qi Yuan , Hittelman Walter N. , Winkles Jeffrey A. , Tran Nhan L. , Rosenblum Michael G.
Published: April 2023

Supplementary materials and methods.
Video 1. Time-lapse DIC Imaging from Near Infrared Photoimmunotherapy in the Treatment of Disseminated Peritoneal Ovarian Cancer
Authors: Sato Kazuhide , Hanaoka Hirofumi , Watanabe Rira , Nakajima Takahito , Choyke Peter L. , Kobayashi Hisataka
Published: April 2023

Video 1. Time-lapse DIC Imaging. Time-lapse sequential DIC images (video) showed swelling and then shrinkage of the cell after NIR light irradiation in cells treated with tra-IR700 (50 min observation). Flashing light is NIR light irradiation (2 J/cm2).(10sec interval, total 50min)
Supplementary Figures 1-8 from Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC
Authors: Zhou Hong , Mohamedali Khalid A. , Gonzalez-Angulo Ana Maria , Cao Yu , Migliorini Mary , Cheung Lawrence H. , LoBello Janine , Lei Xiudong , Qi Yuan , Hittelman Walter N. , Winkles Jeffrey A. , Tran Nhan L. , Rosenblum Michael G.
Published: April 2023

Supplementary Figures 1-8. Supplementary Figure 1: TWEAK is internalized and degraded following binding to Fn14-positive cells Supplementary Figure 2: Surface plasmon resonance analysis of TWEAK Supplementary Figure 3: GrB-TWEAK specifically internalizes into Fn14-expressing MDA-MB-231 cells Supplementary Figure 4: Effect of GrB-TWEAK in combination with chemotherapeutic agents on MDA-MB-231 cells Supplementary Figure 5: Caspase-independent PARP cleavage Supplementary Figure 6: Expression of PI-9 in various cancer cell lines Supplementary Figure 7: Change in body weight of mice from the xenograft experiments Supplementary Figure 8: Schematic of GrB-Fc-IT4 fusion protein
Supplementary Table S1 from Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma
Authors: Shirota Tomoki , Ojima Hidenori , Hiraoka Nobuyoshi , Shimada Kazuaki , Rokutan Hirofumi , Arai Yasuhito , Kanai Yae , Miyagawa Shinichi , Shibata Tatsuhiro
Published: April 2023

Multivariate analysis regarding to overall survival in IHCC.
Supplementary Figure 7 from Significance of Polypyrimidine Tract–Binding Protein 1 Expression in Colorectal Cancer
Authors: Takahashi Hidekazu , Nishimura Junichi , Kagawa Yoshinori , Kano Yoshihiro , Takahashi Yusuke , Wu Xin , Hiraki Masayuki , Hamabe Atsushi , Konno Masamitsu , Haraguchi Naotsugu , Takemasa Ichiro , Mizushima Tsunekazu , Ishii Masaru , Mimori Koshi , Ishii Hideshi , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Immunohistochemical analysis of primary tumor and lymph node with/without tumor metastasis for PTBP1. In lymph node metastasis, metastatic lesions were positive for PTBP1 to the contrary, no staining was observed in intact lymph node in independent two cases. Scale bar: 100 ÃŽÂ¼m.
Supplementary Figure 6 from Significance of Polypyrimidine Tract–Binding Protein 1 Expression in Colorectal Cancer
Authors: Takahashi Hidekazu , Nishimura Junichi , Kagawa Yoshinori , Kano Yoshihiro , Takahashi Yusuke , Wu Xin , Hiraki Masayuki , Hamabe Atsushi , Konno Masamitsu , Haraguchi Naotsugu , Takemasa Ichiro , Mizushima Tsunekazu , Ishii Masaru , Mimori Koshi , Ishii Hideshi , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Immunohistochemical analysis of primary tumor for PTBP1 (Upper) and CDK11p58 (lower). The expression of PTBP1 and CDK11p58 was significantly correlated (P=0.025).
Supplemental table 4 from Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia
Authors: Liao Zhiyong , Gu Lei , Vergalli Jenny , Mariani Samanta A. , De Dominici Marco , Lokareddy Ravi K. , Dagvadorj Ayush , Purushottamachar Puranik , McCue Peter A. , Trabulsi Edouard , Lallas Costas D. , Gupta Shilpa , Ellsworth Elyse , Blackmon Shauna , Ertel Adam , Fortina Paolo , Leiby Benjamin , Xia Guanjun , Rui Hallgeir , Hoang David T. , Gomella Leonard G. , Cingolani Gino , Njar Vincent , Pattabiraman Nagarajan , Calabretta Bruno , Nevalainen Marja T.
Published: April 2023

Supplementary Table 4: Genes down-regulated (> 2-fold) by Stat5-shRNA and IST5-002 in K562
Supplementary Figure 5 from Significance of Polypyrimidine Tract–Binding Protein 1 Expression in Colorectal Cancer
Authors: Takahashi Hidekazu , Nishimura Junichi , Kagawa Yoshinori , Kano Yoshihiro , Takahashi Yusuke , Wu Xin , Hiraki Masayuki , Hamabe Atsushi , Konno Masamitsu , Haraguchi Naotsugu , Takemasa Ichiro , Mizushima Tsunekazu , Ishii Masaru , Mimori Koshi , Ishii Hideshi , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

(A) Strategy for detecting the CD44 variant region. Arrows indicate primers listed in Supplemental Table S1. (B) RT-PCR followed by electrophoresis for CD44 variant region in CRC cell lines. (C) Sequence analysis.
Supplemental Table 3 from Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia
Authors: Liao Zhiyong , Gu Lei , Vergalli Jenny , Mariani Samanta A. , De Dominici Marco , Lokareddy Ravi K. , Dagvadorj Ayush , Purushottamachar Puranik , McCue Peter A. , Trabulsi Edouard , Lallas Costas D. , Gupta Shilpa , Ellsworth Elyse , Blackmon Shauna , Ertel Adam , Fortina Paolo , Leiby Benjamin , Xia Guanjun , Rui Hallgeir , Hoang David T. , Gomella Leonard G. , Cingolani Gino , Njar Vincent , Pattabiraman Nagarajan , Calabretta Bruno , Nevalainen Marja T.
Published: April 2023

Supplementary Table 3: Genes up-regulated (> 2-fold) by Stat5-shRNA and IST5-002 in K562
Supplemental Figure 4 from Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells
Authors: Tsai Yu-Chieh , Ho Pei-Yin , Tzen Kai-Yuan , Tuan Tsung-Fan , Liu Wei-Lin , Cheng Ann-Lii , Pu Yeong-Shiau , Cheng Jason Chia-Hsien
Published: April 2023

Western blotting of T24 cell lysate precipitated with EGFR antibody
Supplemental Figure 3 from Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells
Authors: Tsai Yu-Chieh , Ho Pei-Yin , Tzen Kai-Yuan , Tuan Tsung-Fan , Liu Wei-Lin , Cheng Ann-Lii , Pu Yeong-Shiau , Cheng Jason Chia-Hsien
Published: April 2023

Western blotting of T24 cell lysates treated with chemical cross-linking
Supplemental Figure 2 from Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells
Authors: Tsai Yu-Chieh , Ho Pei-Yin , Tzen Kai-Yuan , Tuan Tsung-Fan , Liu Wei-Lin , Cheng Ann-Lii , Pu Yeong-Shiau , Cheng Jason Chia-Hsien
Published: April 2023

The radiosensitizing effect of erlotinib in HER2 knocked-down NTUB1 cells also emphasizes the synergism between EGFR and HER2 in determining radiosensitivity
Supplement Figure S5 from Aromatase Inhibitor–Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer
Authors: Khatri Raju , Shah Preeti , Guha Rupa , Rassool Feyruz V. , Tomkinson Alan E. , Brodie Angela , Jaiswal Anil K.
Published: April 2023

Supplement Figure S5. Model showing AI-mediated down regulation of INrf2 led to increased Nrf2 and drug resistance.
Supplement Figure S3 from Aromatase Inhibitor–Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer
Authors: Khatri Raju , Shah Preeti , Guha Rupa , Rassool Feyruz V. , Tomkinson Alan E. , Brodie Angela , Jaiswal Anil K.
Published: April 2023

Supplement Figure S3. MCF-7Ca, LTLTCa and LTLTCa-Nrf2KD cells sensitivity to doxorubicin and etoposide.
Supplemental Materials and Methods from An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma
Authors: Lamhamedi-Cherradi Salah-Eddine , Menegaz Brian A. , Ramamoorthy Vandhana , Aiyer Ramani A. , Maywald Rebecca L. , Buford Adrianna S. , Doolittle Dannette K. , Culotta Kirk S. , O'Dorisio James E. , Ludwig Joseph A.
Published: April 2023

Supplemental Materials and Methods. Gene expression profiling and analysis
Supplement Figure S2 from Aromatase Inhibitor–Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer
Authors: Khatri Raju , Shah Preeti , Guha Rupa , Rassool Feyruz V. , Tomkinson Alan E. , Brodie Angela , Jaiswal Anil K.
Published: April 2023

Supplement Figure S2. Additional drug resistance proteins in letrozole sensitive MCF-7Ca and resistant LTLTCa and anestrazole sensitive AC1 and resistant ANAR cells.
Supplement Figure S1 from Aromatase Inhibitor–Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer
Authors: Khatri Raju , Shah Preeti , Guha Rupa , Rassool Feyruz V. , Tomkinson Alan E. , Brodie Angela , Jaiswal Anil K.
Published: April 2023

Supplement Figure S1. Chemical Structures of Letrozole, Anastrozole, and Exemestane
Supplementary Figure 2 from SNAI2 Modulates Colorectal Cancer 5-Fluorouracil Sensitivity through miR145 Repression
Authors: Findlay Victoria J. , Wang Cindy , Nogueira Lourdes M. , Hurst Katie , Quirk Daniel , Ethier Stephen P. , Staveley O'Carroll Kevin F. , Watson Dennis K. , Camp E. Ramsay
Published: April 2023

Supplemental Figure 2. A ) qPCR analysis of miR-145 in SW620 cells transiently transfected with miR-145 or scrambled control normalized to RNU6B. B) qPCR analysis of nanog, myc, SNAI2 and Vimentin mRNA expression in SW620 cells transiently transfected with miR-145 (grey bars) or scrambled control (black bars) normalized to GAPDH. *P<0.02, **P<0.001. C) qPCR analysis of miR-145 in HT29 cells transiently transfected with miR-145 or scrambled control normalized to RNU6B.
Supplemental Figure 2 from An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma
Authors: Lamhamedi-Cherradi Salah-Eddine , Menegaz Brian A. , Ramamoorthy Vandhana , Aiyer Ramani A. , Maywald Rebecca L. , Buford Adrianna S. , Doolittle Dannette K. , Culotta Kirk S. , O'Dorisio James E. , Ludwig Joseph A.
Published: April 2023

Supplemental Figure 2. Nuclear, cytoplasmic and total RHA levels are identical between sensitive and YK-Resistant ES cell lines.
Supplemental Figure 1 from An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma
Authors: Lamhamedi-Cherradi Salah-Eddine , Menegaz Brian A. , Ramamoorthy Vandhana , Aiyer Ramani A. , Maywald Rebecca L. , Buford Adrianna S. , Doolittle Dannette K. , Culotta Kirk S. , O'Dorisio James E. , Ludwig Joseph A.
Published: April 2023

Supplemental Figure 1. Gene expression changes between sensitive and YK-resistant ES cell lines